Galmed Announces ARRIVE Study Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
H.C. Wainwright Remains Bullish on Galmed Pharma (GLMD) Followng Sell Off
February 15, 2018 8:58 AM ESTH.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that the ARRIVE study did not meet its primary endpoint of improvement in liver fat at 12 weeks. Shares closed at $5.45, down -42.4%, after recovering somewhat... More
H.C. Wainwright Remains Bullish on Galmed Pharma (GLMD) Followng Sell Off
February 15, 2018 8:58 AM ESTH.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that the ARRIVE study did not meet its primary endpoint of improvement in liver fat at 12 weeks. Shares closed at $5.45, down -42.4%, after recovering somewhat... More
